Satoshi Shoii - My portal

Profile Information

Affiliation: Respiratory Medicine and Infectious Disease, Medical and Dental Hospital, Niigata University

Researcher number: 90882994
J-GLOBAL ID: 202101004106435307
researchmap Member ID: R000022156

Research Interests

Research Areas

Other / Other / lung cancer

Research History

Apr, 2017 - Present

teaching assistants, Medical and Dental Hospital Respiratory Medicine and Infectious Disease, Niigata University

Education

Jul, 2012 - Mar, 2020

Graduate School of Medicine, Niigata University

Papers

Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease.

Yusuke Sato, Satoshi Watanabe, Takeshi Ota, Kohei Kushiro, Toshiya Fujisaki, Miho Takahashi, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Satoshi Hokari, Rie Kondo, Masachika Hayashi, Hiroyuki Ishikawa, Takao Miyabayashi, Tetsuya Abe, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Nobumasa Aoki, Yasuyoshi Ohshima, Toshiyuki Koya, Toshiaki Kikuchi

Translational lung cancer research, 10(7) 3132-3143, Jul, 2021
Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy.

Satoshi Watanabe, Takeshi Ota, Masachika Hayashi, Hiroyuki Ishikawa, Aya Otsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Takao Miyabayashi, Satoru Miura, Hiroshi Tanaka, Tetsuya Abe, Masaaki Okajima, Masaki Terada, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Toshiaki Kikuchi

Cancer medicine, 9(9) 3070-3077, May, 2020
First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations

Feb, 2020
Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study

Dec, 2019
Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.

Yu Saida, Satoshi Watanabe, Tetsuya Abe, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Kenichi Koyama, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Takashi Ishida, Hiroki Tsukada, Masato Makino, Akira Iwashima, Kazuhiro Sato, Naoya Matsumoto, Hirohisa Yoshizawa, Toshiaki Kikuchi

Thoracic cancer, 10(11) 2106-2116, Nov, 2019
Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.

Miyuki Sato, Satoshi Watanabe, Hiroshi Tanaka, Koichiro Nozaki, Masashi Arita, Miho Takahashi, Satoshi Shoji, Kosuke Ichikawa, Rie Kondo, Nobumasa Aoki, Masachika Hayashi, Yasuyoshi Ohshima, Toshiyuki Koya, Riuko Ohashi, Yoichi Ajioka, Toshiaki Kikuchi

PloS one, 14(4) e0215292, 2019
A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer.

Rie Kondo, Satoshi Watanabe, Satoshi Shoji, Kosuke Ichikawa, Tetsuya Abe, Junko Baba, Junta Tanaka, Hiroki Tsukada, Masaki Terada, Kazuhiro Sato, Yoshie Maruyama, Masato Makino, Akira Hirata, Hiroshi Tanaka, Toshiyuki Koya, Hirohisa Yoshizawa, Toshiaki Kikuchi

Oncology, 94(4) 223-232, 2018
Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.

Ko Sato, Satoshi Watanabe, Aya Ohtsubo, Satoshi Shoji, Daisuke Ishikawa, Tomohiro Tanaka, Koichiro Nozaki, Rie Kondo, Masaaki Okajima, Satoru Miura, Junta Tanaka, Takuro Sakagami, Toshiyuki Koya, Hiroshi Kagamu, Hirohisa Yoshizawa, Ichiei Narita

BMC cancer, 16 222-222, Mar 15, 2016
DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations

Koichiro Nozaki, Hiroshi Kagamu, Satoshi Shoji, Natsue Igarashi, Aya Ohtsubo, Masaaki Okajima, Satoru Miura, Satoshi Watanabe, Hirohisa Yoshizawa, Ichiei Narita

PLoS ONE, 9(10) e111019-e111019, Oct 24, 2014